Patents by Inventor Gerald Reese

Gerald Reese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues
    Patent number: 9975932
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: May 22, 2018
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • VARIANTS OF GROUP 5 ALLERGENS OF THE TRUE GRASSES HAVING REDUCED ALLERGENEITY DUE TO MUTAGENESIS OF PROLINE RESIDUES
    Publication number: 20180002387
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: September 11, 2017
    Publication date: January 4, 2018
    Applicant: Merck Patent GmbH
    Inventors: Martin WALD, Andreas NANDY, Helmut FIEBIG, Bernhard WEBER, Helga KAHLERT, Gerald REESE, Oliver CROMWELL
  • VARIANTS OF GROUP 5 ALLERGENS OF THE TRUE GRASSES HAVING REDUCED ALLERGENEITY DUE TO MUTAGENESIS OF PROLINE RESIDUES
    Publication number: 20150140024
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: December 17, 2010
    Publication date: May 21, 2015
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Variants of group 6 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues
    Patent number: 8999348
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • VARIANTS OF GROUP 6 ALLERGENS OF THE TRUE GRASSES HAVING REDUCED ALLERGENEITY DUE TO MUTAGENESIS OF PROLINE RESIDUES
    Publication number: 20150071953
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 12, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Martin WALD, Andreas NANDY, Helmut FIEBIG, Bernhard WEBER, Helga KAHLERT, Gerald REESE, Oliver CROMWELL
  • VARIANTS OF GROUP 6 ALLERGENS OF THE TRUE GRASSES HAVING REDUCED ALLERGENEITY DUE TO MUTAGENESIS OF PROLINE RESIDUES
    Publication number: 20130224251
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: December 17, 2010
    Publication date: August 29, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • USE OF RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FOR THE TREATMENT OF TYPE 1 HYPERSENSITIVITY IN A LIVING ANIMAL INCLUDING HUMANS
    Publication number: 20090191157
    Abstract: The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament for the prevention and/or treatment of type I hypersensitivity in a living animal including humans. The invention further relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein the heterologous nucleic acid is incorporated into a non-essential region of the genome of the MVA, the heterologous nucleic acid is under the control of, e.g. a vaccinia virus-specific promoter and, the heterologous nucleic acid is selected from the group of nucleic acids encoding an allergen selected from the group of weed pollens, grass pollens, tree pollens, mites, animals, fungi, insects, rubber, worms, human autoallergens, and foods.
    Type: Application
    Filed: March 14, 2007
    Publication date: July 30, 2009
    Applicant: PAUL-ENRLICH-INSTITUT BUNDESAMT FUER SERA UND IMPFSTOFFE
    Inventors: Melanie Albrecht, Gerd Sutter, Yasemin Suezer, Gerald Reese, Stefan Vieths, Caroline Staib